Shoppers in the clinic might soon have a new tool: researchers are developing a blood test that predicts how illnesses will unfold and whether treatments will work, potentially helping doctors triage patients faster and deliver more personalised care.
Essential Takeaways
- What it measures: detects RNA markers in whole blood that reveal which genes are switching on or off and whether activity is ramping up or down.
- Early forecasting: a focused panel of markers can predict who will deteriorate or recover within hours or days, sometimes before PCR or symptoms appear.
- Broad tests: method showed promise across fever in children, viral challenge studies (flu and COVID-19), HIV, TB complications and inflammatory bowel disease therapy response.
- Practical feel: uses routine blood draws, computational analysis; results could be rapid once pipelines are clinicalised.
- Timescale: researchers say a working clinical test could be developed in as little as five years with further validation.
A glimpse into a patient’s future, from a single blood sample
Researchers at Imperial College London have adapted advanced RNA analysis so a single blood sample does more than diagnose , it forecasts. The test picks up subtle RNA patterns that signal whether a patient’s immune response is accelerating or winding down, giving clinicians a sense of trajectory rather than a snapshot. That dynamic read feels decisive: you’re not just told where someone is now, but where they’re heading in the next few hours or days.
The technique evolved from single-cell RNA velocity methods and was tuned for whole-blood samples, so it captures broad systemic responses. According to the team, those patterns can separate people who will recover quickly from those who’ll need intensive care, which matters a lot during busy hospital shifts and seasonal surges.
How the method actually works , simple idea, complex maths
At its heart the approach reads RNA markers produced as genes switch on and off during illness. The original RNA velocity idea looks at whether gene activity is increasing or decreasing; the Imperial group extended that to whole blood and built VeloCD, a computational pipeline that compares an individual’s changing expression patterns to known courses of disease. You get a prognosis signal without needing repeated tests over days.
It’s a neat piece of cross-disciplinary work: bioinformaticians, mathematicians and clinicians combined high-dimensional geometry and dynamics with real patient data to turn noisy biology into usable forecasts.
Tested across different illnesses , surprisingly broad promise
The team validated VeloCD using multiple datasets, including a large European study of nearly 400 children admitted with fever and human viral challenge trials where healthy adults were exposed to influenza or SARS‑CoV‑2. In the paediatric cohort they narrowed thousands of markers to a panel of just 59 that reliably separated mild, moderate and severe outcomes, flagging kids likely to deteriorate. In the challenge trials, early blood samples predicted who would go on to become infected even before PCR confirmation.
Beyond acute infections, the method also showed potential in spotting complications in HIV and tuberculosis and predicting response to inflammatory bowel disease therapies after a first dose , so it isn’t limited to one narrow use-case.
Why this could change triage and treatment decisions
Clinicians often make rapid decisions with limited data; a prognostic blood test could shift that balance by identifying who needs urgent care, who can safely go home, and who’s likely to benefit from a particular drug. That’s the practical promise: faster, more personalised choices at the bedside. The team’s patent filings and the availability of the VeloCD code on GitHub suggest they’re positioning this for development into a commercial clinical assay.
Of course, translation isn’t automatic , large-scale validation, regulatory approval, and integration into hospital workflows take time , but the researchers cautiously estimate a five-year horizon for a deployable test if development proceeds well.
What patients and clinicians should know now
For patients, the idea is reassuring: one routine blood draw could soon give a clearer picture of what’s coming, reducing uncertainty and unnecessary admissions. For clinicians, the tool could be another layer of evidence to guide decisions, especially in emergency and infectious-disease settings. Implementation will require standardised sampling, robust computational pipelines and buy-in from labs and regulators.
Meanwhile, the research community has been open about methods and data sources, which helps reproducibility; VeloCD’s GitHub release is a good sign for transparency and wider testing before clinical roll‑out.
It’s a small change in testing that could make a big difference at the bedside.
Source Reference Map
Story idea inspired by: [1]
Sources by paragraph:
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
10
Notes:
The article was published on 6 May 2026, and the information is current and original. No evidence of recycled or outdated content was found. ([imperial.ac.uk](https://www.imperial.ac.uk/news/articles/2026/blood-test-could-help-predict-disease-progression-and-how-well-treatment-will-work-/?utm_source=openai))
Quotes check
Score:
10
Notes:
Direct quotes from Dr. Claire Dunican and Dr. Myrsini Kaforou are consistent across sources, with no discrepancies noted. ([imperial.ac.uk](https://www.imperial.ac.uk/news/articles/2026/blood-test-could-help-predict-disease-progression-and-how-well-treatment-will-work-/?utm_source=openai))
Source reliability
Score:
10
Notes:
The lead source is Imperial College London’s official news release, a reputable institution. The article is not based on a press release but on original research published in Nature Communications. ([nature.com](https://www.nature.com/articles/s41467-026-71685-5?utm_source=openai))
Plausibility check
Score:
10
Notes:
The claims are plausible and supported by the referenced study. The methodology and potential applications are consistent with current scientific understanding. ([nature.com](https://www.nature.com/articles/s41467-026-71685-5?utm_source=openai))
Overall assessment
Verdict (FAIL, OPEN, PASS): PASS
Confidence (LOW, MEDIUM, HIGH): HIGH
Summary:
The article is original, current, and based on reputable sources. All claims are supported by the referenced study, and there are no significant concerns regarding accuracy or reliability.